ORBi: Detailled Reference

Article (Scientific journals)

Prevention de la fracture de la hanche chez le sujet age: ou en sommes-nous en 2003?

Reginster, Jean-Yves; Lecart, Marie-Paule; Sarlet, Nathalie et al.

2003 • In Revue Médicale de Liège, 58 (4), p. 183-90

Peer reviewed

Permalink
https://hdl.handle.net/2268/34168

PubMed
12875249

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

PREVENTION DE LA FRACTURE DE LA HANCHE CHEZ LE SUJET AGE.pdf

Publisher postprint (466.58 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Aged; Calcitonin/therapeutic use; Calcium/therapeutic use; Dietary Supplements; Diphosphonates/therapeutic use; Estrogen Replacement Therapy; Female; Hip Fractures/prevention & control; Humans; Organometallic Compounds/therapeutic use; Osteoporosis, Postmenopausal/prevention & control; Parathyroid Hormone/therapeutic use; Selective Estrogen Receptor Modulators/therapeutic use; Thiophenes/therapeutic use; Vitamin D/therapeutic use

Abstract :

[en] Osteoporosis in very elderly subjects is now considered, in most developed and several developing countries as a major social, clinical and financial burden. While many compounds have been investigated in the prevention or treatment of spinal fractures, few of them have unequivocally demonstrated their ability to reduce the risk of non vertebral and more specifically hip fractures in the very elderly. This situation may seem highly paradoxical since hip fractures are unanimously considered to be the most dramatic and disabling consequence of osteoporosis. The present article reviews the current evidence available to justify anti-osteoporotic medications to be recommended to very elderly subjects, in the perspective of reducing their risk of appendicular fractures.

Disciplines :

General & internal medicine

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Lecart, Marie-Paule ; Centre Hospitalier Universitaire de Liège - CHU > Rhumatologie

Sarlet, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur

Halkin, V.

Language :

French

Title :

Prevention de la fracture de la hanche chez le sujet age: ou en sommes-nous en 2003?

Alternative titles :

[en] Prevention of hip fractures in the elderly: where are we in 2003?

Publication date :

2003

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

58

Issue :

4

Pages :

183-90

Peer reviewed :

Peer reviewed

Available on ORBi :

since 01 January 2010

Statistics

Number of views

124 (5 by ULiège)

Number of downloads

145 (3 by ULiège)

More statistics

Scopus citations^®

0

Scopus citations^®
without self-citations

0

OpenAlex citations

0

Bibliography

Cauley JA, Thompson DE, Ensrud KC, et al. - Risk of mortality following clinical fractures. Osteoporos Int, 2000, 11, 556-561.
Block JE, Stubbs H. - Hip fracture-associated mortality reconsidered. Calcif Tissue Int, 1997, 61, 84.
Keene GS, Parker MJ, Pryor GA. - Mortality and morbidity after hip fractures. BMJ, 1993, 307, 1219-1250.
Reginster J-Y, Gillet P, Ben Sedrine W, et al. - Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics, 1999, 15, 507-514.
Reginster J-Y, Gillet P, Gosset C. - Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull World Health Organ, 2001, 79, 942-946.
Gillet P, Reginster J-Y. - Increased number of hip fractures. Lancet, 1999, 33, 2160-2161.
Kannus P, Niemi S, Parklesti J, et al. - Hip fractures in Finland between 1970 and 1977 and predictions for the future. Lancet, 1999, 353, 802-805.
Delmas PD, Confavreux E, Ganero P, et al. - A combination of low doses of 17b-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int, 2000, 11, 177-187.
Torgerson DJ, Bell-Syer SE. - Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trials. JAMA, 2001, 285, 2891-2897.
Lufkin EG, Wahner HW, O'Fallon, et al. - Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med, 1992, 117, 1-9.
Reginster J-Y, Bruyere O, Audran M, et al. - Do estrogens effectively prevent osteoporosis-related fractures? Calcif Tissue Int, 2000, 67, 191-194.
Cauley JA, Black DM, Barret-Connor E, et al. - Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/progestin Replacement Study (HERS). Am J Med, 2001, 110, 442-450.
Komulainen MH, Kroger H, Tuppurainem MT, et al. - HRT and Vitamin D in prevention of non-vertebral fractures in postmenopausal women: a 5-year randomised trial. Maturitas, 1998, 31, 45-54.
Mosekilde L, Beck-Nielsen H, Sorensen OH, et al. - Hormone replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas, 2000, 36, 181-193.
Writing Group For Women's Health Initiative Investigators. - Risks and benefits of estrogen plus proestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288, 321-333.
Fletcher SW, Colditz GA. - Failure of estrogen plus progestin therapy for prevention. JAMA, 2002, 288, 366-368.
Cauley JA, Seeley DG, Ensrud K, et al. - Estrogen replacement therapy and fractures in older women. Ann Intern Med, 1995, 122, 9-16.
Reginster J-Y, Denis D, Albert A, et al. - 1-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet, 1987, 1481-1483.
Halkin V, Reginster JY. - Efficacy and tolerability of calcitonin in the prevention and treatment of osteoporosis. Biodrugs, 1998, 4, 295-300.
Kanis JA, Johnell O, Gullberg B, et al. - Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ, 1992, 305, 1124-1128.
Overgaard K, Hansen MA, Jensen SB, et al. - Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ, 1992, 305, 556-561.
Chesnut CH, Siverman S, Andriano K, et al. - A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med, 2000, 109, 267-276.
Kanis JA, Mc Closkey. - Effect of calcitonin on vertebral and other fractures. QJM, 1999, 92, 143-149.
Cummings S, Chapurlat R. - What PROOF proves about calcitonin and clinical trials. Am J Med, 2000, 109, 330-331.
Recker RR, Hinders S, Davies KM, et al. - Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res, 1996, 11, 1961-1966.
Reid JR, Ames RW, Evans MC, et al. - Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med, 1995, 98, 331-335.
Lips P, Graafmans WC, Ooms ME, et al. - Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med, 1996, 124, 400-406.
Dawson-Hughes B, Harris SS, Krall EA, et al. - Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med, 1997, 337, 670-676.
Chapuy MC, Arlot ME, Duboeuf F, et al. - Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med, 1992, 327, 1637-1642.
Chapuy M, Arlot M, Delmas P, et al. - Effect of calcium and cholacalciferol treatment for three years on hip fractures in elderly women. BMJ, 1994, 308, 1081-1082.
Storm T, Thamsborg G, Steiniche T, et al. - Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med, 1990, 322, 1265-1271.
Watts NB, Harris ST, Genant HK, et al. - Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med, 1990, 323, 73-79.
Van Staa TP, Abenhaim L, Cooper C. - Use of cyclical etidronate and prevention of non-vertebral fractures. Brit J Rheumatol, 1998, 37, 87-94.
Black DM, Cummings SR, Karpf DB, et al. - Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, 1996, 348, 1535-1541.
Cummings SR, Black DM, Thompson DE, et al. - Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial. JAMA, 1998, 280, 2077-2082.
Karpf DB, Shapiro DR, Seeman E, et al. - Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA, 1997, 277, 1159-1164.
Reginster J-Y, Minne HW, Sorensen OH, et al. - Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int, 2000, 11, 83-91.
Harris ST, Watts NB, Genant HK, et al. - Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA, 1999, 282, 1344-1352.
McClung MR, Geusens P, Miller P, et al. - Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med, 2001, 344, 333-340.
Reginster J-Y. - Risedronate treatment and extended fracture protection in postmenopausal women. Clin Exp Rheumatol, 2001, 19, 625-626.
Neer RM, Arnaud CD, Zanchetta JR, et al. - Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344, 1434-1441.
Ettinger B, Black D, Mitlak B, et al. - Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA, 1999, 282, 637-645.
Delmas P, Genant H, Crans G, et al. - Prevalent vertebral fracture severity predicts subsequent vertebral and nonvertebral fracture risk in postmenopausal women with osteoporosis: Results from the multiple outcomes of Raloxifene evaluation (MORE) trial. Osteoporos Int, 2002, in print.
Meunier PJ, Roux C, Ortolani S, et al. - Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos Int, 2002, 13, 045.
Reginster JY, Sawicki A, Devogelaer JP, et al. - Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis. Osteoporos Int, 2002, 13, 014.

Similar publications